Adam’s Take

Insights and opinions from senior biotech writer Adam Feuerstein

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

Adam's Take

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

By Adam Feuerstein

Adam's Take

Biotech saw positive results this quarter; shares still tanked. Here are some explanations

By Adam Feuerstein

Adam's Take

The top-performing biotech stock this year has surged on flimsy data

By Adam Feuerstein

peanuts
Adam's Take

AnaptysBio peanut allergy shot improves tolerance, aided by generous reading of data

By Adam Feuerstein

IP Phone
Adam's Take

Biotech CEOs talk a lot. Here’s how to spot the red flags in what they’re saying

By Adam Feuerstein

Martin Shkreli & Benjamin Brafman
Adam's Take

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

By Adam Feuerstein

Kopy Katz
Adam's Take

Marinus Pharma finds the biotech imitation game can only last so long

By Adam Feuerstein

Killer T cells surround a cancer cell
Adam's Take

A biotech seeking IPO riches limited disclosure of patient deaths tied to immunotherapy

By Adam Feuerstein

Adam's Take

Omeros cataract surgery drug sales vanished and now a loan default is a real risk

By Adam Feuerstein

Chest thumping
Adam's Take

Biotech is full of chest-thumping press releases. This one thumps really hard

By Adam Feuerstein and Damian Garde

Adam's Take

Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint

By Adam Feuerstein

Adam's Take

In biotech, it pays to be bullish on Alzheimer’s trials, even when facts stand in the way

By Adam Feuerstein

Adam's Take

A biotech goes quiet on pivotal trial of a cancer vaccine, as doctors, investors, patients are left to wonder

By Adam Feuerstein

Adam's Take

Omeros cataract surgery drug faces steep sales declines with expiration of favorable Medicare reimbursement

By Adam Feuerstein

Adam's Take

The biotech M&A spotlight shifts to Biogen, with some clear candidates to acquire

By Adam Feuerstein

Scott Gottlieb
Adam's Take

An open letter to Dr. Scott Gottlieb on FDA transparency

By Adam Feuerstein

JP Morgan 2017
Adam's Take

We went to #JPM18 with burning questions about biotechs. We got some answers

By Adam Feuerstein

JP Morgan 2017
Adam's Take

It’s a pivotal moment for Dermira and its acne medication. What are its chances?

By Adam Feuerstein

JP Morgan 2017
Adam's Take

JPM is like a biotech dating game, just ask these questions before hooking up

By Adam Feuerstein

Knee Xray
Adam's Take

With an arthritis drug no better than common saline, Ampio Pharma’s shot at FDA approval is dim

By Adam Feuerstein

Cranky toddler
Adam's Take

Biotech stocks in 2017 were a lot like toddlers. Here’s why

By Adam Feuerstein

storm clouds
Adam's Take

For biotech analysts, the outlook for 2018 is dark and stormy

By Adam Feuerstein

Good/Bad CEO 2017
Adam's Take

Maraganore runs away with best biopharma CEO award; Soon-Shiong wins prize for worst

By Adam Feuerstein

Worst Biotech CEOs 2017
Adam's Take

And now, your nominees for worst biopharma CEO of 2017. Let the voting begin!

By Adam Feuerstein

ASH 2017 story card
Adam's Take

ASH winners and losers: Hemophilia therapies show promise, Syros stumbles

By Adam Feuerstein

Best Biotech CEOs 2017
Adam's Take

Introducing the nominees for best biopharma CEO of 2017. Vote for your favorite!

By Adam Feuerstein

Adam's Take

Biotech stocks, on a strong run all year, are taking a breather

By Adam Feuerstein

Adam's Take

Here’s why investors in Geron, Puma Bio, Intrexon, and Ziopharm should worry

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy